Kissei Pharmaceutical Co., Ltd

We at Kissei, as our management philosophy, hope to contribute to freeing people from the pain and suffering of disease. And for the past half century since our founding, we have moved ever forward with research into original medications, continuing with the development of new pharmaceutical products which contribute to the advancement of medical science. The needs for medical therapy for people are becoming more advanced and multi-faceted. At the same time, the research and development of new, more effective and safer pharmaceuticals are hoped for by physicians and pharmacists. Amidst the background of this era Kissei is moving ahead emphasizing specific research and development areas as an R&D-oriented pharmaceutical company in order to be able to respond to such demands and aiming toward the development of pharmaceutical products which can contribute to medical science. In order to continue as a company possessing a global vision and meaning, we are determined to work for the future health of the people throughout the world. Consequently, we are devoting our best efforts to the research and development of new and useful pharmaceutical products and therapeutic food products and are moving forwards, step by step, towards becoming a comprehensive health company.

Contact Details: 15375 Barranca Parkway, Suite A-111 Irvine California 92618 United States of America Tel: 1-949-453-0110 Fax: 1-949-453-0440 Email: public_relations@kissei.co.jp WWW: www.kissei.co.jp/

Loading...

Press Releases on Kissei Pharmaceutical Co., Ltd:
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days	8th May, 2009	Watson Pharmaceuticals, Inc.	- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data - CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a new,
Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients	28th April, 2009	Watson Pharmaceuticals, Inc.	- Uniquely Selective Agent Offers Significant Improvement - CHICAGO, April 28 /PRNewswire-FirstCall/ -- Data to be presented at the American Urological Association's (AUA) Annual Conference
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)	7th April, 2009	Watson Pharmaceuticals, Inc.	-- New product, now available in pharmacies, will provide rapid symptom relief for number one reason men visit a urologist -- CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson
Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes	5th August, 2008	Watson Pharmaceuticals, Inc.	CORONA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- A paper published in the current issue of Reviews in Urology (2008; 10(2):85-91) concludes that urologists and other physicians treating benign

BioNews Results for Kissei Pharmaceutical Co., Ltd:
KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments	Entrepreneur.com:  Nov 16 2009 4:20AM Matching: pharmaceutical
Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009...	Zibb:  Nov 16 2009 6:39AM Matching: pharmaceutical
Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009...	Zibb:  Nov 16 2009 6:39AM Matching: pharmaceutical
Pharmaceuticals : EmailWire.Com SEO Press Release Distribution Services and PharmaNewsWire.Com Present Free Ph	TMC Net:  Nov 14 2009 6:23PM Matching: pharmaceutical
KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments	Montana's News Station:  Nov 14 2009 5:59PM Matching: pharmaceutical
Promote your company here: BioNewsCast - Press Release Distribution	→View more Kissei Pharmaceutical Co., Ltd news.

Kissei Pharmaceutical Co., Ltd Patents:
US Patent No.	Title
6407139	Neovascularization inhibitor
7087579	Glucopyranosyloxypyrazole derivatives and medicinal use thereof
7115575	Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
7129381	Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
7160555	Immediate release medicinal compositions for oral use
→View more Kissei Pharmaceutical Co., Ltd patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 599 times since April 2007, the link to the organisation's website has been followed 80 times

Recent Search Terms used to find this page: Kissei Pharmaceutical Co. Ltd. in California | kissei pharma | Kissei Pharmaceuticals 2009 | Silodosin Intermediates. | Kissei Pharmaceutical Co | Silodosin intermediates | Kissei pharmaceutical Bioportfolio | Kissei Pharmaceuticals logo | Kissei Pharma USA | .

Search for more companies in Irvine

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Kissei Pharmaceutical Co., Ltd